Today we announced that Spectranetics Corporation (Nasdaq: SPNC), a developer, manufacturer, marketer and distributor of single-use medical devices used in minimally invasive procedures within the cardiovascular system, has selected Clinipace to manage all aspects of a pivotal cardiovascular device clinical study that will serve as the basis for 510(k) notice submission.
Today we announced the financial close to our best year to date, achieving over 800% revenue growth since 2008. The company more than doubled its revenues in 2010 over the prior year, attributable to 16 new projects awarded from 12 new clients.
In addition to conducting several engagements in regulatory consulting, biostatistics and functional monitoring; Clinipace Worldwide was awarded contracts to manage several phase 1, 2 and 3 trials in nephrology/renal, oncology, cardiovascular, and immunology. As a result, the company’s hiring rate grew significantly to support increased demand for its technology-amplified services and therapeutic expertise.
Read the full release.
